Innate Pharma avance le programme de développement clinique de lacutamab
February 09, 2021 01:00 ET
|
INNATE PHARMA
Marseille, 09 févr. 2021 (GLOBE NEWSWIRE) -- Progression de l’essai TELLOMAK : la cohorte 2 de patients présentant un mycosis fongoïde exprimant KIR3DL2 avance au stade 2 plus tôt que prévu La...
Innate Pharma advances lacutamab clinical development program
February 09, 2021 01:00 ET
|
INNATE PHARMA
Marseille, Feb. 09, 2021 (GLOBE NEWSWIRE) -- TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated Company to initiate...
Innate Pharma organise une conférence avec des experts sur le rôle potentiel de lacutamab dans les lymphomes à cellules T
February 03, 2021 01:00 ET
|
INNATE PHARMA
Marseille, 03 févr. 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd'hui qu'elle...
Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas
February 03, 2021 01:00 ET
|
INNATE PHARMA
Marseille, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual key...
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas
February 03, 2021 01:00 ET
|
INNATE PHARMA
MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual...
Un premier anticorps multispécifique engageant les cellules NK d'Innate sélectionné par Sanofi comme candidat-médicament
January 05, 2021 01:00 ET
|
INNATE PHARMA
Marseille, 05 janv. 2021 (GLOBE NEWSWIRE) -- IPH6101/SAR443579 est un anticorps multispécifique engageant les cellules NK (NKCE) via leur récepteur activateur NKp46 et utilisant le format...
Innate's first NK cell engager selected by Sanofi as drug candidate for development
January 05, 2021 01:00 ET
|
INNATE PHARMA
Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) -- IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody formatSelection of IPH6101/SAR443579...
Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development
January 05, 2021 01:00 ET
|
INNATE PHARMA
IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody formatSelection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate ...
Innate Pharma to Participate in Upcoming Investor Conferences
January 04, 2021 01:00 ET
|
INNATE PHARMA
MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior...
Innate Pharma to participate in upcoming investor conferences
January 04, 2021 01:00 ET
|
INNATE PHARMA
Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior...